| Bioactivity | JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities[1]. | ||||||||||||
| Invitro | JAK2-IN-7 (compound 13ac) (0-1000 nM; 2 hours) inhibits JAK2 and STAT5 phosphorylation in a dose-dependent manner in SET-2 and Ba/F3-JAK2V617F cells[1].JAK2-IN-7 (10-160 nM; 24 hours) induces cell arrest in the G0/G1 phase[1].JAK2-IN-7 (0.05-1.6 μM; 2 hours) induces apoptosis in SET-2 cells[1]. Cell Cycle Analysis[1] Cell Line: | ||||||||||||
| Name | JAK2-IN-7 | ||||||||||||
| CAS | 2593402-36-7 | ||||||||||||
| Formula | C26H33N7O | ||||||||||||
| Molar Mass | 459.59 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
JAK2-IN-7
CAS: 2593402-36-7 F: C26H33N7O W: 459.59
JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respecti
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.